JPWO2021132311A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021132311A5
JPWO2021132311A5 JP2021567520A JP2021567520A JPWO2021132311A5 JP WO2021132311 A5 JPWO2021132311 A5 JP WO2021132311A5 JP 2021567520 A JP2021567520 A JP 2021567520A JP 2021567520 A JP2021567520 A JP 2021567520A JP WO2021132311 A5 JPWO2021132311 A5 JP WO2021132311A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
compound according
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021567520A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021132311A1 (https=
JP7662534B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2020/048117 external-priority patent/WO2021132311A1/ja
Publication of JPWO2021132311A1 publication Critical patent/JPWO2021132311A1/ja
Publication of JPWO2021132311A5 publication Critical patent/JPWO2021132311A5/ja
Application granted granted Critical
Publication of JP7662534B2 publication Critical patent/JP7662534B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021567520A 2019-12-24 2020-12-23 脂肪族酸アミド誘導体 Active JP7662534B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019232927 2019-12-24
JP2019232927 2019-12-24
PCT/JP2020/048117 WO2021132311A1 (ja) 2019-12-24 2020-12-23 脂肪族酸アミド誘導体

Publications (3)

Publication Number Publication Date
JPWO2021132311A1 JPWO2021132311A1 (https=) 2021-07-01
JPWO2021132311A5 true JPWO2021132311A5 (https=) 2023-12-12
JP7662534B2 JP7662534B2 (ja) 2025-04-15

Family

ID=76574184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021567520A Active JP7662534B2 (ja) 2019-12-24 2020-12-23 脂肪族酸アミド誘導体

Country Status (14)

Country Link
US (3) US12503463B2 (https=)
EP (1) EP4082616B1 (https=)
JP (1) JP7662534B2 (https=)
KR (1) KR20220120625A (https=)
CN (1) CN114981264B (https=)
AU (1) AU2020413284A1 (https=)
BR (1) BR112022011844A2 (https=)
CA (1) CA3161806A1 (https=)
ES (1) ES3040677T3 (https=)
HU (1) HUE072877T2 (https=)
MX (1) MX2022007947A (https=)
PL (1) PL4082616T3 (https=)
PT (1) PT4082616T (https=)
WO (1) WO2021132311A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220120625A (ko) * 2019-12-24 2022-08-30 스미토모 파마 가부시키가이샤 지방족 산 아미드 유도체
JP7655885B2 (ja) * 2021-06-30 2025-04-02 住友ファーマ株式会社 脂肪族酸アミド誘導体を含有する医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880930A (en) 1987-11-30 1989-11-14 New James S Psychotropic acyclic amide derivatives
EP0732332B1 (en) 1995-03-17 2001-12-19 Aventis Pharmaceuticals Inc. Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation
US5880121A (en) * 1996-01-05 1999-03-09 Hoechst Marion Roussel Inc. 4,5-dihydronaphth (1,2-c) isoxazoles and derivatives thereof
JP4497815B2 (ja) 2001-02-16 2010-07-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド 新規な複素環式アミド誘導体およびドーパミンd3受容体リガンドとしてのその使用
FR2827287B1 (fr) * 2001-07-13 2003-10-31 Servier Lab Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2006508101A (ja) 2002-11-08 2006-03-09 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー フェニルアルキルおよびピリジルアルキルピペラジン誘導体
AU2006239302B2 (en) 2005-04-26 2011-07-07 Hypnion, Inc. Benzisoxazole piperazine compounds and methods of use thereof
PL392436A1 (pl) 2010-09-17 2012-03-26 Adamed Spółka Z Ograniczoną Odpowiedzialnością Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego
WO2014079155A1 (zh) * 2012-11-26 2014-05-30 辽宁贝雷生物制药有限公司 苯并五元氮杂环基哌嗪或哌啶衍生物的用途
KR20220120625A (ko) * 2019-12-24 2022-08-30 스미토모 파마 가부시키가이샤 지방족 산 아미드 유도체

Similar Documents

Publication Publication Date Title
JP2019094345A5 (https=)
JP2018502877A5 (https=)
JP2019517487A5 (https=)
JP2018509418A5 (https=)
JP2016515561A5 (https=)
RU2016138118A (ru) Азолины
JP2013532652A5 (https=)
JP2005502621A5 (https=)
JP2018524390A5 (https=)
JP2016517417A5 (https=)
JP2018502148A5 (https=)
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
JP2016503797A5 (https=)
JP2019527233A5 (https=)
JP2017511378A5 (https=)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2019535723A5 (https=)
JP2019527724A5 (https=)
JP2020511536A5 (https=)
JPWO2021132311A5 (https=)
JP2013542267A5 (https=)
JP2018503680A5 (https=)
RU2013136861A (ru) Новое производное индола или индазола или его соль
JP2020512356A5 (https=)
RU2018106498A (ru) Производные 5-(N-конденсированный трициклический арил-тетрагидроизохинолин-6-ил) пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека